Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790296 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related Fatigue
A Phase 2 study, sponsored by UConn Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00790296 is a Phase 2 study that was terminated before completion, run by UConn Health. The registered enrollment target is 11 participants.
The verdict
NCT00790296, a Phase 2 study, was terminated before completion, sponsored by UConn Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate thyrotropin releasing hormone (TRH) as a treatment for cancer-related fatigue. The central hypothesis of this pilot study is that TRH is more efficacious than placebo in alleviating cancer-related fatigue in patients with breast or prostate cancer.
Interventions
- DRUG Placebo
- DRUG Thyrotropin releasing hormone (TRH)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2006-12 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00790296
The ClinicalTrials.gov registry entry for NCT00790296 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UConn Health, which has 178 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00790296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00790296 about?
NCT00790296 is a clinical study titled "Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related Fatigue". The primary objective of the study is to evaluate thyrotropin releasing hormone (TRH) as a treatment for cancer-related fatigue. The central hypothesis of this pilot study is that TRH is more efficacious than placebo in alleviating cancer-related fatigue in patients with breast or prostate cancer.
What is the current status of trial NCT00790296?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2006-12. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00790296?
The interventions under investigation include: Placebo (DRUG), Thyrotropin releasing hormone (TRH) (DRUG).
Who is sponsoring clinical trial NCT00790296?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.